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Abstract: Melatonin is a widespread molecule among living organisms involved in multiple biological,
hormonal, and physiological processes at cellular, tissue, and organic levels. It is well-known for
its ability to cross the blood–brain barrier, and renowned antioxidant effects, acting as a free
radical scavenger, up-regulating antioxidant enzymes, reducing mitochondrial electron leakage, and
interfering with proinflammatory signaling pathways. Detected in various medicinal and food plants,
its concentration is widely variable. Plant generative organs (e.g., flowers, fruits), and especially
seeds, have been proposed as having the highest melatonin concentrations, markedly higher than
those found in vertebrate tissues. In addition, seeds are also rich in other substances (lipids, sugars,
and proteins), constituting the energetic reserve for a potentially growing seedling and beneficial
for the human diet. Thus, given that dietary melatonin is absorbed in the gastrointestinal tract and
transported into the bloodstream, the ingestion of medicinal and plant foods by mammals as a source
of melatonin may be conceived as a key step in serum melatonin modulation and, consequently,
health promotion.
Keywords: melatonin; bioactive phytochemicals; antioxidants; herbal remedies; tryptophan
derivatives; nutraceuticals
1. Introduction
Melatonin is a tryptophan-derived substituted indoleamine (N-acetyl-5-methoxytryptamine;
Figure 1), widely found in living, evolutionarily distant organisms [1]. This molecule was isolated in
1958 by Lerner et al. [2] from cow pineal gland. For decades, melatonin was considered an animal
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neurohormone with an impact in circadian rhythm regulation, seasonal reproductive cycles, and
mammalian immune system modulation [3,4], but currently these studies are outdated. However,
in the 1980s and later, melatonin was also identified in many non-vertebrates (e.g., cnidarians,
planarians, mollusks, insects, crustaceans) [5,6], and in 1989, it was detected in a phototrophic unicell,
the dinoflagellate Gonyaulax polyedra (current name: Lingulodinium polyedrum) [7], and thereafter
analyzed in detail [8]. Subsequently, in 1995, melatonin was identified in some plant species [9,10]
and, since then, the interest on this molecule by plant physiologists has rapidly increased. In the
1990s, an essential and novel function was discovered and attributed to this molecule—a highly potent
hydroxyl radicals scavenger [11], a finding that was considered the starting point of extensive studies
on melatonin antioxidant protection, which turned out to involve numerous mechanisms beyond
radical scavenging [12–17].
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both water and lipids. Looking at melatonin antioxidant properties, it mainly consists of (1) direct 
scavenging of reactive oxygen (ROS) and reactive nitrogen (RNS) species [18]; (2) acceleration of 
antioxidant enzymes activity [19]; (3) protection against oxidative damage [20]; (4) synergistic effects 
with other antioxidants [21]; and (5) improvement of the electron transport efficiency in 
mitochondrial respiratory chain, limiting free radicals overproduction through electron leakage 
reduction [22,23]. Moreover, not only melatonin, but also its derivatives act as natural electron 
donors, highly efficient against oxidative stress. Melatonin is also able to generate a radical scavenger 
cascade (Figure 2), originating oxidation products, such as β-hydroxymelatonin, cyclic β-
hydroxymelatonin or cyclic melatonin [24], and N1-acetyl-N2-formyl-5-methoxykynuramine 
(AFMK) [25], and to contribute to further ROS elimination [26]. In contrast with other antioxidants, 
this ability makes melatonin effective in protecting organisms against oxidative stress, even in small 
doses [27]. Indeed, the maintenance of a proper redox status in aerobic cells (in mitochondria) is the 
basis for the efficient functioning of their metabolism. Also, it seems to be especially important, when 
an organism, for example, a plant, has a photosynthetic apparatus (in chloroplasts) that is an extra 
endogenous source of free radicals and ROS generation. 
  
Figure 1. Chemical structure and mass spectrum of melatonin fragmentation pattern.
2. Melatonin in Plants
Nowadays, it is widely recognized that melatonin is a universal amphiphilic antioxidant molecule,
able to penetrate all compartments of a cell because of its small size, and good solubility in both water
and lipids. Looking at melatonin antioxidant properties, it mainly consists of (1) direct scavenging
of reactive oxygen (ROS) and reactive nitrogen (RNS) species [18]; (2) acceleration of antioxidant
enzymes activity [19]; (3) protection against oxidative damage [20]; (4) synergistic effects with other
antioxidants [21]; and (5) improvement of the electron transport efficiency in mitochondrial respiratory
chain, limiting free radicals overproduction through electron leakage reduction [22,23]. Moreover,
not only melatonin, but also its derivatives act as natural electron donors, highly efficient against
oxidative stress. Melatonin is also able to generate a radical scavenger cascade (Figure 2), originating
oxidation products, such as β-hydroxymelatonin, cyclic β-hydroxymelatonin or cyclic melatonin [24],
and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) [25], and to contribute to further ROS
elimination [26]. In contrast with other antioxidants, this ability makes melatonin effective in protecting
organisms against oxidative stress, even in small doses [27]. Indeed, the maintenance of a proper redox
status in aerobic cells (in mitochondria) is the basis for the efficient functioning of their metabolism.
Also, it seems to be especially important, when an organism, for example, a plant, has a photosynthetic
apparatus (in chloroplasts) that is an extra endogenous source of free radicals and ROS generation.
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In 1995, two independent papers confirmed the presence of melatonin in higher plants [9,10]. 
Since then, the search for this molecule in many edible plants and medicinal herbs has been 
extensively reported [28–34]. Melatonin has been found inter alia in apple, barley, bean, cucumber, 
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Coffee robusta Coffea canephora Pierr. Bean 5800 [41] 
Coffee arabica Coffea arabica (L.) Bean 6800 [41] 
Black pepper Piper nigrum (L.) Leaf 1093 [42] 
Wolf berry (goji) Lycium barbarum (L.) Fruit 530 [43] 
White radish Raphanus sativus (L.) Bulb 485 [43] 
White mustard Sinapis alba (L.) Seed 189 [1] 
Black mustard Brassica nigra (L.) Seed 129 [1] 
Curcuma Curcuma aeruginosa Roxb. Root 120 [43] 
Wolf berry Lycium barbarum Seed 103 [1] 
Burmese grape Baccaurea ramiflora Lour. Leaf 43.2 [42] 
Fenugreek Trigonella foenum-graecum (L.) Seed 43 [1] 
Almond Prunus amygdalus (Batsch) Seed 39 [1] 
Sunflower Helianthus annuus (L.) Seed 29 [1] 
Fennel Foeniculum vulgare (Gilib.) Seed 28 [1] 
Agati Sesbania glandiflora (L.) Desv. Leaf 26.3 [42] 
Bitter melon Momordica charantia (L.) Leaf 21.4 [42] 
Alfalfa Medicago sativum (L.) Seed 16 [1] 
Green cardamom Elettaria cardamomum (White et Maton) Seed 15 [1] 
Flax Linum usitatissimum (L.) Seed 12 [1] 
Linseed (flax) Linum usitatissimum (L.) Seed 12 [1] 
Java bean Senna tora (L.) Roxb. Leaf 10.5 [42] 
Sesban Sesbania sesban (L.) Merr. Leaf 8.7 [42] 
Anise Pimpinela anisum (L.) Seed 7 [1] 
Celery Apium graveolens (L.) Seed 7 [1] 
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In 1995, two independent papers confirmed the presence of melatonin in higher plants [9,10].
Since then, the search for this molecule in many edible plant and medicinal herbs as b en extensively
reported [28–34]. Melatonin has been found i ter alia in apple, b rley, bean, cucumber, g apes, lupin ,
maize, potato, rice, and tomato, among ot ers (Table 1) [1,28–31,35–39].
Table 1. Melatonin contents in some plant organs [40].
Common Name Latin Name Organ Melatonin [ng g
-1
DW](or FW*)
Reference
Coffee robusta Coffea ca ephora Pierr. Bean 5800 [41]
Coffee arabica Coffea arabica (L.) Bean 6800 [41]
Black pepper Piper nigrum (L.) Leaf 1093 [42]
Wolf berry (goji) Lycium barbarum (L.) Fruit 530 [43]
White radish Raphanus sativus (L.) Bulb 485 [43]
White mustard Sinapis alba (L.) Seed 189 [1]
Black mustard Brassica nigra (L.) Seed 129 [1]
Curcuma Curcuma aeruginosa Roxb. Root 120 [43]
Wolf berry Lycium barbarum Seed 103 [1]
Bur ese grape Baccaurea ramiflora Lour. Leaf 43.2 [42]
Fenugreek Trigonella foen m-graecum (L.) Seed 43 [1]
Almond Prunus amygdalus (Batsch) Seed 39 [1]
Sunflower Helianthus annuus (L.) Seed 29 [1]
Fennel Foeniculum vulgare (Gilib.) Seed 28 [1]
Agati Sesbania glandiflora (L.) Desv. Leaf 26.3 [42]
Bitter melon Momordica charantia (L.) Leaf 21.4 [42]
Alfalfa Medicago sativum (L.) Seed 16 [1]
Green cardamom Elettaria cardamomum (White et Maton) Seed 15 [1]
Flax Linum usitatissimum (L.) Seed 12 [1]
Linseed (flax) Linum usitatissimum (L.) Seed 12 [1]
Java bean Senna tora (L.) Roxb. Leaf 10.5 [42]
Sesban Sesbania sesban (L.) Merr. Leaf 8.7 [42]
Anise Pi pinel anisum (L.) Seed 7 [1]
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Table 1. Cont.
Common Name Latin Name Organ Melatonin [ng g
-1
DW](or FW*)
Reference
Celery Apium graveolens (L.) Seed 7 [1]
Coriander Coriandrum sativum (L.) Seed 7 [1]
Poppy Papaver somniferum (L.) Seed 6 [1]
Walnut Juglans regia (L.) Seed 3.5 [44]
Milk thistle Silybum marianum (L.) Seed 2 [1]
Sweet cherries Prunus avium (L.) Fruit 120* [45]
Tart cherries Prunus cerasus (L.) Fruit 19.5* [46]
Grapevine Vitis vinifera (L.) Fruit 18* [47]
Cherry Prunus cerasus (L.) Fruit 18* [46]
Corn Zea mays (L) Seed 14-53* [24]
Cucumber Cucumis sativus (L) Seed 11-80* [24]
Strawberry Fragaria x ananassa (Duch.) Fruit 11.3* [48]
Pomegranate Punica granatum (L.) Fruit 5.5* [49]
Tall fescue Festuca arundinacea Seed 5.3* [10]
St. John’s wort Hypericum perforatum (L.) Flower 4* [50]
Lupine Lupinus albus (L.) Seed 3.8* [36]
Tomato Solanum lycopersicum (L.) Fruit 2.5* [51]
Fever few Tanacetum parthenium (L.) Leaf 2* [50]
St. John’s wort Hypericum perforatum (L.) Leaf 2* [50]
Oat Avena sativa (L.) Seed 1.8* [10]
Corn Zea mays (L.) Seed 1.4* [10]
Grapevine Vitis vinifera (L.) Fruit 1.2* [52]
Rice Oryza sativa japonica (L.) Seed 1* [10]
* corresponds to FW. DW, dry weight; FW, fresh weight.
Studies in 108 herbs species, commonly used in Chinese Medicine, revealed the presence of
melatonin at concentrations ranging from a few to several thousand nanograms per gram of tissue [43],
meaning that they are good natural sources of this health-related molecule. Melatonin was also
detected and quantified in roots, shoots, leaves, flowers, fruits, and seeds, but its highest levels have
been found in reproductive organs, particularly in seeds. This abundance is probably related to the
impact of reproductive organs in plant species survival, and to their need to effectively defend them
against various environmental stresses, including secondary oxidative stress [1,24]. On the other hand,
it was also stated that melatonin concentrations differ not only among species, but also among different
varieties of the same species [31]. Thus, it has been suggested that variations in melatonin contents
might result not only from the distinct extraction and detection techniques applied, but also from
the fact that both the biosynthesis and metabolism of this indoleamine are affected and modified by
distinct environmental conditions [51]. This aspect partially explains why different organs of the same
plant contain various amounts of melatonin during consecutive morphological and physiological
stages of development. Generally, it was noticed that various plant species rich in melatonin has a
greater capacity of stress tolerance [53–56], an aspect that turned attention to melatonin as a potentially
effective agent in improving plant stress defense. Moreover, exogenous melatonin can also be used as
a crop biostimulating agent [57–59].
In scientific literature, the term phytomelatonin sometimes appears, which is mostly applied to
distinguish the endogenous melatonin synthesized by plants from the exogenous one, applied to them,
although chemically, the molecule is the same. Not least interesting to highlight is that, in medicinal
plants, including pyrethrum maruna (Tanacetum parthenium L.) and St. John’s wort (Hypericum perforatum
L.), the levels of melatonin are sometimes higher than those found in animals [50], although both
organisms possess the required enzymatic systems for melatonin biosynthesis (Figure 3). Moreover, and
contrarily to animals, plants are also able to synthesize the melatonin precursor, tryptophan, an aromatic
amino acid. Theoretically, it is constantly available for further transformations in plants, while in
animals, it can only be supplied by foods. Still, and besides its in vivo synthesis, plants can also absorb
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melatonin provided exogenously from the environment, accumulating it at high concentrations [24,60];
thus, they can be conceived as great sources of melatonin and other indoleamines for animals.Cells 2019, 8, x FOR PEER REVIEW 5 of 22 
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Regarding melatonin biosynthetic pathways, they are similar between animals (humans) and plants
(Figure 3). Briefly, they consist of the same precursor, tryptophan, and two common derivatives,
serotonin and N-acetyl-serotonin. However, the tryptophan conversion to serotonin in animals occurs via
5-hydroxy-tryptophan, whereas in plants, it occurs via tryptamine. In the latter, serotonin can be converted
into melatonin via N-acetyl-serotonin (as in animals) and 5-methoxy-tryptamine [62–64]. Thus, it is feasible
to suppose that indole derivative transformations in plants are richer and multidirectional when compared
with animals.
In all organisms, the primary function of melatonin is to act as a free radical’s scavenger and
ROS detoxifying agent. These reactive species are highly generated during the aerobic metabolism,
mainly in mitochondria and chloroplasts; thus, it has been hypothesized that these organelles are
sites of melatonin biosynthesis in plants [45]. Indeed, it is believed that archaic purple non-sulphur
bacteria (i.e., Rhodospirillum rubrum) and photosynthetic cyanobacteria after ingestion by primer
eukaryotes eventually transformed via endosymbiosis into mitochondria and chloroplasts, respectively,
or more advanced eukaryotes. According to the hypothesis of Tan et al. [45], in most organisms,
if not all, the capacity of melatonin biosynthesis may have been transferred from mitochondria and
chloroplasts to other cell compartments, such as endoplasmic reticulum and cytosol. In fact, during
evolution, involved genes in melatonin biosynthesis found in R. rubrum or other non-sulphur purple
bacteria and cyanobacteria were gradually integrated into the nuclear genome, although some of
Cells 2019, 8, 681 6 of 23
them may have also been lost [65]. Anyway, it seems that the hypothesis related to the original
location of melatonin biosynthesis in mitochondria and chloroplasts may help in answering the
question of why the melatonin content in green plants is markedly higher than in animals. Moreover,
the contributory factor in explaining this phenomenon seems to be related to the presence of two
organelles (mitochondria and chloroplasts) able to synthesize melatonin in plants in comparison to
animals, which have only mitochondria.
Taking a look at the predicted protective effect of melatonin on plant photosynthesis, it has also
been confirmed [66,67]. Broadly, melatonin affects photosynthetic processes efficiency by the following:
(1) delaying chlorophylls degradation [68,69]; (2) increasing CO2 uptake [70,71]; and (3) accelerating
the electron transport [72,73]. However, besides its direct and indirect properties against oxidative
damage, which is secondary to all abiotic and biotic stresses, melatonin also stimulates a number
of specific plant defence mechanisms at the proteomic [74,75] and genetic [55,76,77] levels, against
various stresses, like cold, drought, high temperatures, strong light, heavy metals, and pathogens,
among others.
As a structural analog of indole-3-acetic acid (IAA), a common auxin also derived from tryptophan,
melatonin, is involved in plant growth regulation and development [33,34,78]. There are also earlier
reports that indicate the role of melatonin in plant circadian rhythm regulation and photoperiodic
responses; however, to precisely explain these phenomena requires further investigations [23].
The studies on melatonin in plants indicate that it is a very important molecule for them. Although it
is not classified as a phytohormone, melatonin does perform crucial signaling functions at a multilevel
metabolic network, especially in plant–environment interactions [79]. Thus, as melatonin was identified
in a huge number of edible plants and herbs, its presence in food products and beverages derived
from plants is not surprising. Various beverages, for example, beer, coffee, red vine, and several types
of tea [31], as well as olive and mustard oil [80], have been studied as potential natural sources of
this indoleamine.
3. Melatonin in Humans: A Key Emphasis in Biological Activity
Circadian clocks have developed to adapt biological functions to specific times within the day or
night [81]. This clock controls diurnal sleeping and waking cycles, body temperature, and hormone
release. Suprachiasmatic nucleus (SCN) cells receive neural cues from the retina and send the
information obtained on photoperiodic status to the pineal gland, which then synthesizes them and
releases melatonin, distributing the time signal to the rest of the body [82].
With concerns to melatonin biosynthesis in humans, the exogenous amino acid tryptophan
through the action of tryptophan hydroxylase (TP5H) and aromatic acid decarboxylase (AADC)
enzymes is converted to the neurotransmitter, serotonin. In the subsequent step, serotonin is
converted into melatonin through the influence of arylalkylamine N-acetyltransferase (AANAT) and
hydroxyindole-O-methyltransferase (HIOMT) enzymes (Figure 3) [83].
Melatonin synthesis proceeds for 24 h/day. However, more is produced and released into the
blood at night. In an adult human, approximately 30 µg of melatonin is synthesized per day, and
the maximum concentration in the blood is reached at the mid-dark period. There is no storage of
melatonin in the pineal gland; it is released into the bloodstream and then rapidly degraded in the
liver [84]. The liver hydroxylates melatonin in the C6 position under cytochrome P450 monooxygenases
A2 and 1A action, which is then converted to the sulfate derivative, a 6-sulfatoxymelatonin, which is
removed from the body through urine [85].
In the circulatory system, melatonin may be bound to albumin and hemoglobin [84], but it
is primarily transported by the serum albumin. The amphiphilic nature of melatonin allows it to
easily cross cellular and morphophysiological barriers, including the blood–brain barrier [86]. It was
shown, using 2-dimensional X-ray diffraction measurements, that melatonin can reorganize the lipid
membranes, with the final effects depending on its concentration. Thus, at low concentrations,
the presence of melatonin-enriched patches was observed in the cell membrane, while at high
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concentrations, a highly ordered uniform melatonin structure throughout the membrane became
apparent. In fact, understanding this phenomenon could help explain the molecular basis of melatonin’s
actions, such as its anti-amyloidogenic in the brains of Alzheimer’s disease (AD) patients [87],
antioxidant and photoprotective actions, as well as the fact that melatonin so easily penetrates into
different cell compartments [88]. Moreover, in mammalian cell transport systems, GLUT/SLC2A and
PEPT1/2 were shown to have an active role in facilitating melatonin transport across membranes,
especially into mitochondria [14].
Some studies report that foodstuffs intake containing melatonin may contribute to raising the
level of this molecule in the serum and 6-sulfatoxymelatonin concentrations in urine [89]. Melatonin
produced by many organs, including pineal gland, retina, gastrointestinal tract, skin, lymphocytes,
and bone marrow [90], and possibly in every organ, it is also effectively taken from foodstuffs rich in
this molecule [13].
As an endogenous indoleamine, melatonin has huge physiological functions, including regulation
of the sleep promotion, circadian rhythms, mood, immunomodulatory actions, neuroprotective
effects, bone growth, hormonal regulation, tumor suppression, defense against oxidative stress, and
anti-inflammatory activity [91]. It may also be considered a therapeutic alternative to fighting bacterial,
viral, and parasitic infections [91]. Generally, melatonin is not toxic and is safe; even in extreme
doses, only mild adverse effects in a few individuals, such as dizziness, headache, nausea, and
sleepiness, have been reported [92]. Although, because of a lack of studies, the intake of exogenous
melatonin in pregnant and breastfeeding is not recommended. The main roles and functions of
melatonin are presented in Figure 4. Not least important to highlight is that melatonin production in
humans decreases with age (i.a., it is already depressed in women during menopause) and it seems
to be especially depressed in certain diseases, such as in AD, cardiovascular disorders, and certain
malignancies. Also, a reduced melatonin output has been linked to insomnia in older patients and a
higher prevalence of cancer [93].
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3.1. Regulation of the Circadian Rhythm, Biological Clock, and Sleep/Wake Cycle
One of the earliest known functions of melatonin is its impact on circadian rhythms’ regulation.
Light is the environmental factor known to affect melatonin secretion. Melatonin acts directly on the
SCN and modulates clock function. Circadian signals from the SCN are transmitted to the pineal gland
via a multi-synaptic pathway, which involves the neural projections from the SCN to the paraventricular
nuclei (PVN), the intermediolateral cell column of spinal cord (IML), superior cervical ganglion (SCG),
and finally to the pineal gland (SCN→ PVN→ IML→ SCG→ pineal gland) [94]. The pineal gland is
located in the midline of the brain. It transduces light and dark information to the entire body when it
Cells 2019, 8, 681 8 of 23
releases melatonin [95]. The behavioral effect of this information is a result of the specific evolutionary
habits of the species. For instance, in humans, the night is a time of sleep, where melatonin promotes it
and also depresses body temperature at night [96], while in many other species (e.g., wolf or owl),
the nocturnal peak of melatonin secretion is associated with wakefulness and high activity.
3.2. Melatonin Receptors
Melatonin has specific receptors and intracellular targets in different cell types in animals to
regulate many physiological functions, through modification of adenylate cyclase, guanylate cyclase,
and phospholipase C activities, and membrane channels for calcium and potassium mediate melatonin
signaling [97]. Specifically, the MT1 (high affinity) and MT2 (low affinity) melatonin receptors are
G-protein-linked [98], and affect protein kinase activity through inhibition of adenylyl (cAMP) and
guanylyl (cGMP) cyclase, respectively. These receptors regulate ion flux inside the cell via activation
phospholipase [97]. Melatonin receptor 3 (MT3) is probably a quinone reductase 2 (QR2). This enzyme
has an important role in free radicals’ neutralization in the organism [99]. However, MT3 receptors
have not yet been found in humans, although they are expressed in various tissues of hamsters and
rabbits [100]. Also, a putative nuclear receptor is the retinoid Z receptor α (RORa/RZR), though its
function is still unclear [101].
Melatonin receptors are widely distributed in the body. They exist in cardiovascular, immune
and endocrine systems, reproductive and gestational tissues, and even in the skin and gastrointestinal
tract [100]. GPR50, a melatonin-related receptor, has also been identified and is detected in various
brain structures and peripheral tissues in humans [102,103].
3.3. Receptor-Mediated Activities
Many of melatonin’s actions are mediated through an interaction with the G-protein coupled
membrane-bound melatonin receptors MT1 and MT2, the quinone reductase II enzyme (MT3), or
indirectly via nuclear orphan receptors of the RORa/RZR family [100].
Previous studies have shown that melatonin improves induced pluripotent stem cells’ (iPSCs’)
proliferation and differentiation into neurons through activating phosphatidylinositide 3 kinases
(PI3K)/AKT signal pathway, through modulation of MT1 and MT2 membrane receptor [104]. Moreover,
melatonin is effective in treating periodontitis, mucositis, and even some cancers. Melatonin
has promising antineoplastic potential owing to its antiproliferative, cytostatic, antimetastatic,
and proapoptotic effects against tumor cells [105]. It enhances osseointegration and bone
regeneration [76]. The ubiquitin-proteasome system controls osteoblasts and osteoclasts proliferation
by providing a mechanism for regulating proteins recirculation. Also, melatonin interacts with the
ubiquitin-proteasome system, thus contributing to bone regeneration regulation [106].
Melatonin, an ubiquitously-acting molecule, also regulates hormones’ release, especially those
involved on seasonal reproduction and preservation of gamete quality. It inhibits the release of
prolactin, luteinizing hormone, and stimulating follicle hormone during seasonal reproductive
quiescence. A large body of experimental evidence indicates that melatonin has beneficial effects
on reproduction in both male and female animals. In male reproduction, it regulates the following:
(1) secretion of two key neurohormones, gonadotropin-releasing hormone (GnRH) and luteinizing
hormone (LH), through binding to specific receptors and inhibition of both GnRH and LH production;
(2) synthesis of testosterone and testicular maturation; and (3) prevention of testicular damage induced
by environmental toxins or inflammation [107]. Also, experimental data demonstrated that melatonin
increases the maternal-to-zygotic transition (MZT)-related genes expression in vitrified-warmed mouse
MII oocytes [108].
In the recent past, several studies have highlighted the location of MT1 and MT2 receptors in
different regions of the brain and retina. This has led to the manipulation of these anatomic sites specific
to the disease processes [109]. MT1 and MT2 receptors have been found in all layers of the neural retina
and the retinal pigmented epithelium. Melatonin protects skin cell against UV damage and regulates
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skin pigmentation. It also has protective effects on retinal pigment epithelial cells, photoreceptors, and
ganglion cells. Moreover, when melatonin interacts with calmodulin, it directly antagonizes calcium
ions binding to calmodulin [102].
Melatonin is also a compound with sufficient therapeutic benefits to prevent cardiovascular
diseases [85,99]. It contributes to the cardioprotective effect of lethal ischemia-reperfusion injuries [110],
and this effect is in part mediated by the activation of the tumor necrosis factor alpha (TNFα) and signal
transducer and activator of transcription 3 (STAT3), which both play a key role in enhancement of the
pro-survival the SAFE (survivor activator factor enhancement) pathway for cardioprotection [99].
Melatonin may also be beneficial in the treatment of dopamine-related disorders. Evidence
suggests that it modulates dopaminergic pathways involved in the coordination of body movement
disorders in humans [111]. Also, melatonin inhibits insulin release from β-cells in the pancreas. There
is also an interrelationship between melatonin and insulin in type 1 diabetic (T1D) and type 2 diabetic
(T2D) rats and humans. The effects of melatonin on insulin secretion may involve melatonin receptors
(MT1 and MT2), inhibiting the adenylyl cyclase (AC)/cyclic AMP system [112]. Thus, melatonin may
be promising in diabetes management via the above-mentioned processes.
3.4. Nonreceptor-Mediated Effects
At the whole, redox status plays an essential role in many cellular processes. ROS and RNS
overproduction (generate oxidative and/or nitrosative stress) affects several biomolecules, including
lipids, proteins, and DNA, consequently triggering some serious diseases, such as cancer, diabetes,
and neurological and cardiologic disorders [113–115]. Melatonin is a highly effective ROS eliminator
and exhibits numerous protective actions against oxidative stress, and is even reported to be 10×
more powerful than vitamin E in scavenging ROS/RNS [116]. Melatonin receptor-independent actions
include excessive ROS and RNS neutralization, generated as a result of UV and ionizing radiation,
heavy metal toxicity, drugs and alcohol toxicity, and so on. Melatonin’s main metabolites include
cyclic 3-hydroxymelatonin and N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) [117]. Figure 5
illustrates melatonin’s antioxidant cascade reactions in mammals [118].
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Melatonin protects the brain via the immune system, and as a defense against ROS/RNS damages.
It has beneficial effects against mitochondrial dysfunction [119], considered a major causative agent
in neurodegenerative diseases, such as AD, Huntington’s disease (HD), and Parkinson’s disease
(PD) [85,120,121]. Some studies indicate that melatonin in the range of 50–100 mg/day is effective
in reducing oxidative mitochondrial dysfunction in experimental models of AD, HD, and PD. It is
equally effective, in vitro and in vivo, in preventing oxidative/nitrosative stress-induced mitochondrial
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dysfunctions [85]. Lipid peroxidation and ROS/RNS generation in neurons also lead to neuropsychiatric
and neurodegenerative disorders; thus, because of the strong antioxidant activity and diverse pleiotropic
actions of melatonin, it has been proposed an effective neuroprotective agent in diverse neuropsychiatric
disorders [122].
Recently, melatonin has been proposed as a potent mitochondrial protector [14,123]. Indeed,
melatonin was detected at higher concentrations in mitochondria than in other organelles or subcellular
compartments. To highlight that, mitochondria comprise the major cellular site of ROS production
during respiration and adenosine triphosphate (ATP) synthesis. In addition, high levels of melatonin
are accumulated in these organelles against a concentration gradient by mitochondrial membrane
transporters. Not least important to highlight is that, according to the endosymbiotic theory on the origin
of mitochondria from melatonin-producing bacteria, these organelles likely evolutionarily inherited
the capacity to synthesize melatonin. Therefore, as recently reported in excellent reviews, melatonin
can scavenge ROS, thus decreasing mitochondrial oxidative damages, consequently preserving their
structural and functional integrity, and finally delaying cellular aging and the onset of age-related
disorders [13,123].
Melatonin also possesses anti-inflammatory and anti-apoptotic properties. It protects cells against
damage and improves cell survival and proliferation [124]. Further, melatonin, owing to its low toxicity
and high efficacy in reducing oxidative damage, has been recommended as a protective candidate
against typical chemical weapons [125] and even as a snakebite therapy [126].
As an anti-inflammatory molecule, melatonin differentially modulates pro-inflammatory
enzymes; controls inflammatory mediators’ production, such as cytokines and leukotrienes; and
regulates leukocytes lifespan through interfering with apoptotic processes. Indeed, it selectively
inhibits inflammation by stimulating pro-inflammatory mediators, such as arachidonic and
5-hydroxyeicosatetraenoic (5-HETE) acids, through phospholipase A2 (PLA2) and 5-lipoxygenase
(5-LOX) activation, respectively [83].
The experimental evidence has yielded promising results regarding the role of melatonin as an
anti-carcinogenic agent [105]. It is beneficial in preventing and treating several common cancers [127].
Indeed, melatonin appears to promote apoptotic death in some cancer cells, while being protective to
normal cells [107]. Melatonin has cytoprotective properties in the reproductive system by reducing
apoptosis of the oocyte and granulosa cells [86]. Melatonin also inhibits the hypoxia-inducible factor 1
alpha (HIF-1α) and HIF-1α-inducible gene [128].
In conclusion, melatonin has attracted the attention of many scientists owing to its unique
physiological functions and pharmacological properties. In the last decade, hundreds of scientific
publications have focused on melatonin. It is a regulatory molecule that orchestrates a variety of
physiological and pathophysiological processes. Beneficial effects of melatonin in various models
of disease provide support/robustness for the general comment that “melatonin helps against
everything” [129]. Melatonin is used by millions of people around the world to potentially retard
aging diseases, improve sleep, mitigate jet-lag symptoms, and treat depression [130], besides being a
safe, cheap, natural, and widely available molecule with multiple therapeutic benefits.
4. Melatonin Supplementation and its Health Effects for Humans
Individuals living in highly industrialized countries look for melatonin-supplemented drugs and
pills as a way to improve sleep and rest, as the main advantages include quicker times to fall asleep
and quicker ”jet-lag” reductions. On the other hand, some of the users also referred to experience
headaches, dizziness, and sleepiness during daylight hours (overdose symptoms), but these made be
placebo effects [96]. Initially, many studies have shown that exogenous melatonin was able to improve
sleep, probably because of the chronobiotic role of this molecule. Indeed, it aids in the adjustment
and maintenance of a regular circadian rhythmicity [131]. However, there are many other potential
health effects attributed to melatonin’s application. For example, melatonin supplementation is helpful
in inflammatory markers, hypertension, oxidative stress, and metabolic syndrome [132]. In one of
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these studies, a positive correlation was found between melatonin-rich foods and clinical-metabolic
indicators. Also, melatonin concentration varies markedly among various foods, and its concentration
may change during the food products’ preparation [133].
4.1. Melatonin and Inflammation
Melatonin inhibits cyclooxygenase-2 (COX-2), the enzyme responsible for the inflammatory
cascade. Moreover, melatonin decreases pain perception during the inflammatory response, but
may also enhance the analgesic effects of nonsteroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen [134]. In 2002, El-Shenawy and coworkers determined the mechanism of anti-inflammatory
and anti-nociceptive (sensory nervous system response to pain) effects of melatonin [135]. For that,
the authors injected carrageenan (1%) into the rats’ paw to induce inflammation. Rats either received
a diluent or melatonin 30 min pre-injection and they analyzed its potential for paw edema at 1, 2, 3,
and 4 h post-carrageenan injection. Paw thickness aided in determining the inflammation level and
edema formation. Nociception was tested based on rat vocalization after electrical stimulation of the
tail. Melatonin, given intraperitoneally to rats 30 min before the carrageenan injection, was found to
decrease swelling of the paw induced by the toxin. At doses of 0.5 and 1 mg/kg, melatonin was found to
inhibit carrageenan-induced edema in 20.5% and 29.6%, respectively, when compared with the control
at 4 h post-carrageenan injection. Melatonin at both 0.5 and 1 mg/kg also exerted anti-nociceptive
effects on electrical stimulation in the rat trail test, and the increase in nociceptive thresholds to
pain brought on by the electrical pain at 4 h post-treatment was 29.6 and 39.6%, respectively. When
melatonin was given in combination with a COX-1 and COX-2 inhibitor, indomethacin (5 mg/kg, i.p.),
30 min in advance of carrageenan injection, the anti-inflammatory effects were enhanced by 23% in
the paw edema model. A higher melatonin dose (5 mg/kg) further increased the anti-nociceptive
effects of indomethacin. Anti-inflammatory and anti-nociceptive effects of the COX inhibitor slightly
increased with 0.5 mg/kg melatonin. Also, it was also observed that melatonin elevates the cysteamine
(300 mg/kg, s.c.) effect in the carrageenan-induced rat paw edema model. No anti-inflammatory effects
were found using melatonin doses of 20 and 40 µg per paw. On the basis of the results, the authors
concluded that melatonin has anti-inflammatory and anti-nociceptive effects in rats and may enhance
the action of indomethacin [135].
4.2. Melatonin and Wound Repair
Melatonin promotes the immune system response early in the wound healing process and may
even aid in healing and scar formation quality. In the study of Pugazhenthi et al. [136] with male
rats, a positive correlation between superficial application of melatonin and scar repair was noted.
Melatonin acts as a strong anti-inflammatory agent, also having positive immunomodulatory effects
under certain conditions. In the cited study, a melatonin injection (1.2 mg/kg) into subdermal tissue in
rats was examined for its ability to inhibit scar formation after an incision made in the skin. Melatonin
treatment improved the scars’ quality by modulating their maturity rate and orientation of the collagen
fibers. Moreover, melatonin depressed nitric oxide (NO) synthesis during the inflammatory process.
In addition, while NO is generally detrimental during inflammation, it has positive effects during
new tissue formation [136]. The subdermal injection of melatonin also expedited the angiogenic
process, through intensifying the new blood vessel formation and increasing the vascular endothelial
growth factor (VEGF) protein expression in granulation tissue formation. An increase in arginase
levels, the enzyme that plays a crucial role in proline biosynthesis [136], was similarly observed.
This amino acid is a factor determining a protein’s quaternary structure, and is very useful during
collagen synthesis and its spatial conformation. This study documents that melatonin, when added
under the epidermis, might be beneficial in improving incision healing and in reducing scar formation.
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4.3. Melatonin and Brain Injury
Brain injury, as a result of stroke and trauma, readily interferes with neurological functions.
In brain injury, inflammation and oxidative stress are commonly involved. Many brain traumas result
in a change in blood flow, which leads to hypoxia. In addition, hypoxia may paradoxically lead to
the so-called “oxygen burst”, which means its incomplete reduction and generation of ROS and free
radicals, which in turn damages cell membranes and impairs cognitive function [137,138]. Melatonin is
also a highly effective antioxidant, free radical scavenger, and anti-inflammatory agent with therapeutic
effects on brain injuries [139–141]. Treatment with melatonin over 30 days in mice with induced stroke
led to a marked improvement in brain cell survival and functional recovery. Several studies have
correlated melatonin administration with the long-lasting improvement of motor and coordination
physiology, which are also common in human strokes [142]. Melatonin levels often drop in patients
who have suffered a severe brain injury, and animal studies have concluded that replenishing melatonin
levels after the injury helps to reduce tissue injuries and also decrease cognitive deficits [143]. Melatonin
also aids in toxic ROS reduction, produced when brain cells are deprived of oxygen, and likewise
reduces the inflammatory systems activation in the brain; these changes are essential in aiding infant
size post-head injury reduction [144]. Melatonin also has a positive impact on memory deficits when
immediately administered after rabbits experience a brain injury [145]. Melatonin also protects fetal
animals’ brains against ischemia/repulsion injury when it occurs during pregnancy [146]. In human
pregnancies, similar injuries may result in cerebral palsy or mental retardation in newborn infants.
Melatonin has been found to prevent learning disorders correlated with brain injuries in infant animals,
and repeated doses have exhibited a further reduction in brain injury [123]. In fact, numerous reports
have confirmed that melatonin supplementation has strong abilities to protect the brain against injury.
4.4. Melatonin and Cardio- and Neuro-Protection
Melatonin also increases the antioxidant enzymes’ activity and also scavenges free radicals
produced during cardiac injury. Because of its direct and indirect antioxidant properties, melatonin
prevents oxidative damage and reduces the size area of heart cell death [147]. Moreover, melatonin
stimulates antioxidant enzymes, while simultaneously down-regulating the pro-oxidant enzymes.
Its administration has also been shown to be effective in reducing hypertension and drugs-induced
cardio-toxicity [147,148]. Moreover, when myocardial infarction (MI) was induced in rats, melatonin
administration (4.5 mg/kg/day) post-MI (via subcutaneous osmotic pumps) significantly lowered the
left ventricular (LV) levels of mRNAs, dihydropyridine receptor (DHPR), ryanodine receptor 2 (RYR2),
and sarco-endoplasmic reticulum Ca2+-ATPase (SERCA2) compared with these measures in control
rats. These authors concluded that melatonin improved the strength of the heart’s pumping action
post-MI under these experimental conditions [96]. Reiter and Tan [147] have also noted that melatonin
protects mitochondria, which is the energy source for cardiac muscle function.
Research focused on the protective role of melatonin in the degree of cardiac injury in patients
undergoing bypass surgery, in 45 patients (45–65 years old), reported that melatonin (10 mg or 20 mg
capsule once daily) increased the ejection fraction associated with a significant decline in heart rate [149].
In addition, melatonin significantly reduced plasma levels of troponin-I, interleukin-1beta, inducible
oxide synthase, and caspase-3 enzymes, in both supplemented groups. The authors concluded that
melatonin supplementation can ameliorate the degree of myocardial ischemic-reperfusion injury. Also,
a study focusing on melatonin effects in 97 normotensive and hypertensive volunteers (63–91 years
old) found that melatonin supplementation (1.5 mg/day for two weeks) had a direct hypotensive
effect [150]. Also, melatonin stabilized the internal temporal order, enhancing the circadian component
and the synchronization between rhythms of different physiological functions.
On the other hand, melatonin administration has also been shown to be useful to improve the
cognitive performance in subjects with mild cognitive impairment (MCI) [151]. Each year, about 12%
of MCI patients eventually develop AD or other types of dementia. In a study of 25 MCI patients,
who received 3–9 mg of melatonin before sleep over 8–9 months exhibited better performance in the
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Mini-Mental State Examination and a cognitive subscale of AD assessment. The authors also reported
that melatonin-supplemented patients had better scores on Rey’s verbal tests, Trail A and B tasks, and
Mattis’ test, but the treatment did not affect the Digit-symbol test score. Finally, it was found that
abnormally high Beck Depression Inventory scores decreased in melatonin-treated patients. Thus,
these studies suggest that melatonin may be useful in the treatment of MCI patients [151].
The use of melatonin to treat neurodegenerative diseases revealed that this molecule was able to
reduce amyloid-beta peptide (Aβ) deposits in the brains of AD patients [87]. This finding indicates
that activated glia due to chronic inflammation correlates with Aβ deposits in the brains of AD
patients. In this study, melatonin’ effects were specifically examined on glia activation and an increase
in learning in amnesic rats, induced by Aβ peptide 25–35, was observed. Cognitive function was
analyzed using the Morris water maze test. The study reported that Aβ 25–35 injected into the rat
hippocampus promoted impairments in learning and memory, which was associated with a rise of
activated glial cells compared to controls. When melatonin was administered at 0.01, 0.1, and 1 mg/kg
over 10 days, learning and memory improved in rats that had received the Aβ 25–35. Melatonin
inhibited pro-inflammatory factors in these animals, and when applied to humans, it may aid in the
treatment of AD patients with regards to memory and learning improvement [87].
A report by Kilic et al. [152] was conducted to identify the potential positive effects of melatonin
in amyotrophic lateral sclerosis (ALS). ALS is a disease that involves oxidative stress in alpha-motor
neurons of the spinal cord. The authors observed that melatonin is a possible neuroprotective compound
and strong antioxidant in this disease model. Experiments were done with different test models: (1) in
cultured motoneuronal cells (NSC-34); (2) in a genetic mouse model of ALS [SOD1 (G93A)-transgenic
mice], and (3) in a group of 31 patients with sporadic ALS. Melatonin decreased glutamate-induced cell
death in cultured motoneurons. In SOD1 (G93A)-transgenic mice, high melatonin doses administered
post-poned disease advancement orally and increased survival. Also, ALS patients receiving a high
dose (300 mg/day) of rectal melatonin over the course, over two years, were found to have normalized
levels of protein carbonyls (an oxidative stress marker) in circulation. The authors concluded that high
melatonin doses are safe for humans and it is suitable for clinical trials to gain information on its effect
as an antioxidant in ALS patients [152].
5. Oral Bioavailability of Plant Melatonin
Exogenously administered melatonin is well absorbed following oral administration, widely
distributed, and virtually completely metabolized in humans [153]. Melatonin receptors are abundant
in the brain and melatonin readily penetrates the blood–brain barrier [154]. Melatonin, when consumed
as a drinking fluid [155] or taken as a galenic tablet [156], is readily absorbed into circulation. Thus,
it would be expected that melatonin from foods would also likely be absorbed. While this may be true,
melatonin uptake from herbal remedies or products, and phytomelatonin oral bioavailability, have not
been well explored.
The study of Yeleswaram et al. [157], assessing the oral bioavailability of synthetic melatonin in rats,
dogs, and monkeys, showed a dose-dependent availability that differed among the species examined.
The dose normalized oral bioavailability following a 10 mg/kg oral dose of melatonin represented 53.5%
in rats, while it was around 100% in dogs and monkeys. However, the oral bioavailability of melatonin
in dogs was found to be decreased to 16.9% following a 1 mg/kg oral dose. In vitro permeability
studies with CACO-2 cells, the model suggested that exogenous melatonin is likely to be well absorbed
in humans [157]. Hattori et al [10] investigated the oral melatonin bioavailability from 24 edible plants
and found that the administration of a diet consisting in plant products rich in melatonin to 48 h fasted
chicks significantly increased the level of circulating melatonin, that is, the daytime melatonin levels
were roughly doubled. Moreover, they found that competes with melatonin binding sites in the rabbit
brain [10].
Melatonin absorbed into feed pellets or into wheat grains that received chicken food also led to
its high initial plasma melatonin concentration, followed by a rapid decrease after 2–3 h; however,
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elevated levels were still detectable up to 24 h after administration. While melatonin absorbed
into cracked wheat grains subsequently washed with ethanol eliminated the initial transitory peak,
it sustained the plasma levels for at least 12 h in the normal nocturnal range (750 pM), and there was
no measurable melatonin increase (<60 pM) 18 h later. The authors concluded that melatonin-treated,
ethanol-rinsed cracked wheat grains could be used to experimentally mimic the long-night plasma
melatonin patterns [158].
Food restriction of rats and then feeding them with regular chow or melatonin-rich (3.5 ng/g FW)
walnuts (Juglans regia L.) was followed by elevated blood melatonin concentrations in animals that had
eaten walnuts (increased from 11.5 to 38.0 pg/mL), compared with rats fed the control diet. Increases
in blood, melatonin were also accompanied by rises in serum antioxidant capacity [44]. However, it is
unclear whether other plant components can trigger or reduce the release or uptake of melatonin into
the gastrointestinal tract or organs involved in metabolism, such as liver [159].
Similar experiments with rats were performed by Aguilera et al. [160], but as a source of
phytomelatonin, they used bean (Phaseolus vulgaris L.) sprouts, that is, the aqueous extract from bean
sprouts. The authors assessed in rats the effect of bean sprout intake on plasma melatonin levels
and its metabolite, 6-sulfatoxymelatonin, in urine. Also, they compared the bioavailability derived
from bean sprouts versus synthetic melatonin. Blood and urine samples were obtained before and
after 90 min of melatonin (phyto- or synthetic) administration via a gavage. The plasma melatonin
levels increased after bean sprout ingestion (16%, p < 0.05). This increment correlated with the urinary
6-sulfatoxymelatonin content, the principal biomarker of plasma melatonin levels (p < 0.01). In contrast
to the previous discussed findings by Reiter, Manchester, and Tan [44], the antioxidant capacity did not
exhibit any significant change. The comparison of bioavailability between bean sprouts phytomelatonin
and synthetic melatonin indicated slightly higher levels of plasma melatonin (17%) in rats fed with the
synthetic melatonin solution [160].
Melatonin Oral Bioavailability in Humans
When looking at melatonin bioavailability, a number of studies already performed report an
extensive variation, even assessing its oral and/or intravenous administration. In addition, and not least
interesting to highlight, is that considerable variations in melatonin aspects related with its absorption,
metabolism, and elimination have also been stated between distinct individuals. These aspects clearly
reflect the need for more in-depth studies on the pharmacokinetic properties of melatonin. For instance,
Andersen et al. [161] conducted a crossover cohort study to determine the pharmacokinetics of 10 mg
oral melatonin or 10 mg intravenous melatonin in healthy male volunteers. Orally administered
melatonin was rapidly absorbed, with Tmax being reached at 41 min; however, the Cmax and the area
under the curve (AUC) varied significantly among volunteers. With regards to oral and intravenous
melatonin elimination half-lives, they were 54 min and 39 min, respectively. Thus, oral melatonin
bioavailability was found to be only 3% with considerable inter-volunteer variability.
The physiological changes in human plasma melatonin have also been investigated after beer
consumption. Eighteen brands of beer containing melatonin up to 170 pg/mL were analyzed. Beer
administered to seven subjects consisting of four men (660 mL) and three females (330 mL) aged between
20 and 30 years resulted in an uptake of 112 ng and 56 ng of melatonin for men and women, respectively.
Melatonin bioavailability from beer was directly proportional to the dose, and serum analysis by
ELISA prior and 45 min post-administration confirmed that melatonin increase in human serum was
related to drinking melatonin-rich beer [162]. In humans, serum melatonin concentrations increase
significantly from 10 to 12 pg/mL at 1 h after a single consumption of 100 mL red wine [80]. The “French
paradox” (high long-life expectancy of the French people, despite its theoretically unhealthy diet rich
in fat), associated with regular consumption of red wine, which includes plant polyphenols, especially
resveratrol, may also be because of the intake of melatonin, which is present in red wine.
Fruits seem to be also a good source of phytomelatonin. Served to 12 healthy male volunteers
for breakfast as either juice extracted from 1 kg of orange or pineapple or two whole bananas,
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containing 302 ng, 150 ng, and 1.7 ng phytomelatonin, respectively, elevated the plasma melatonin
levels, generating characteristic change kinetics over time [163]. A blood sample was collected from
the experimental participants before breakfast (control), as well as 1, 2, and 3 h after consuming the
fruit products. Serum melatonin concentration (assessed by ELISA) increased already at 1 h, reaching
the highest values at the second hour after fruit consumption. The values were significantly increased
for pineapples (146 vs. 48 pg/mL, p = 0.002), oranges (151 vs. 40 pg/mL, p = 0.005), and bananas
(140 vs. 32 pg/mL, p = 0.008), respectively. Between the second and third hours of the experiment,
plasma melatonin levels decreased rapidly in all subjects, reaching values lower than 50 pg/mL after
the third hour. In this experiment, serum antioxidant capacity (estimated by oxygen radical absorbance
capacity (ORAC) and ferric reducing antioxidant power (FRAP) tests) following fruit consumption
was also significantly elevated and was strongly correlated with serum melatonin concentration for all
the three fruits tested [163].
Although many herbs containing significant melatonin amounts are known, except St. John’s
wort, no study reported the oral bioavailability of melatonin from herbal products. The daily treatment
of 13 healthy subjects for three weeks with a hydroethanolic extract of dried flowering tops or aerial
parts of St. John’s wort significantly increased the nocturnal melatonin plasma concentration in these
subjects [164]. However, this study was not very informative because the melatonin concentration in the
extract, and the exact melatonin amount ingested from the plant product, was unknown. Conclusions
were only based on the rise in plasma melatonin levels. Therefore, it is possible to infer that the
incremental rise in melatonin levels may not have been linked to phytomelatonin intake from plant,
but rather occurred as a result of some plant constituents that triggered the release of endogenous
melatonin from the gut.
On the other hand, some authors criticized the studies investigating the measurement of blood and
urine melatonin after the intake of foods containing this molecule, suggesting that the claimed increases
in circulating melatonin are not consistent with the amount of dietary melatonin ingested [165,166].
However, after the administration of a glass of melatonin-enriched red wine, the serum melatonin
levels changed, peaking at 60 min post-intake, supporting the role of absorbed dietary melatonin in
counteracting the physiological decline of its endogenous levels in the bloodstream [89].
6. Conclusions
Therein, the use of dietary melatonin may be extremely beneficial in helping to maximize the
health-promoting effects of medicinal plants and healthy foods in humans, possibly acting in synergy
with other bioactive phytochemicals (i.e., polyphenols) that are ingested daily. However, the current
lack of knowledge on the oral bioavailability of melatonin in the humans diet clearly indicates the
need for more in-depth clinical trials, namely considering the circadian and seasonal variations of
endogenous melatonin and allowing to estimate the amount of melatonin ingested. In fact, as there is
no difference between endogenous and exogenously acquired melatonin, it is very difficult to assess
the dietary contribution in humans.
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